

DOI: 10.21767/2572-5548.100043

Market Analysis Report for COPD and Lungs Conference 2020

Ms Suchi

Chair and Vice President, Global Goodwill Ambassadors, Singapore

* **Corresponding author:** Ms Suchi, Chair and Vice President, Global Goodwill Ambassadors, Singapore; E-mail: suchi11sg@gmail.com

Rec date: Jul 05,2020; **Acc date:** Jul 19, 2020; **Pub date:** Jul 27, 2020

Copyright: © 2020 Suchi , et al. This is an open-access article distributed under the terms of the Creative Commons AttributionLicense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Suchi, et al. (2020) **Market Analysis Report for COPD and Lungs Conference 2020.** Chron Obstruct Pulmon Dis 5.2

Why to Attend???

International Conference on COPD & Lungs 2020 brings together Pulmonologists, Respiratory specialists, Chest medicine specialist, Scientists, Researchers, scholars, students, industry experts to exchange the ideas and researches, technologies in the field of pulmonology and to understand the current state of research and the challenges to future discovery.

The main aim of this International conference on COPD & Lungs 2020 is to provide a platform to students, academicians, and pulmonary practitioners from multiple disciplines to debate and exchange ideas and knowledge. The International COPD market is consider being worth \$9.9 billion presently and is expected to bench a value of \$14.1 billion by 2025. The drugs driving this growth include once-daily LABA/LAMA fixed- dose combinations such as QVA-149, umeclidinium bromide/ vilanterol and olodaterol/tiotropium. The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US\$13.0 billion in 2015 to be worth US \$18.7 billion by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein. North Hemisphere countries trends the international market for

COPD drugs. And it was followed by the European countries market capitalization. The Asia Pacific region is forecast to be the rapid regional for COPD & Asthma market owing to the fastest frequency of asthma & other respiratory diseases in industrial region.

Importance & Scope

This COPD &Lungs 2020 conference is the best platform which helps the pulmonologists and other respiratory care professionals to get the latest trends, innovations and insights in the field of pulmonology to improve patient care. All the researchers working in the field of pulmonology, Respiratory Medicine, lungs diseases, complicated chest infections, Pneumonia, emphysema can be benefited much in this conference.

The global pulmonary drug delivery market is projected to register a CAGR of 6% from 2016 to 2021. Growth in this market is attributed to technological advancements, increasing geriatric population, and growing incidence of respiratory diseases. Growth in online marketing and emerging economics offer significant opportunities for market growth.